270 related articles for article (PubMed ID: 23740105)
21. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy.
Hoff MN; Yapp DT; Yung AC; Oliver TS; Kozlowski P
Int J Radiat Biol; 2008 Mar; 84(3):237-42. PubMed ID: 18300024
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
23. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
24.
Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
26. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Lin LL; Silvoniemi A; Stubbs JB; Rengan R; Suilamo S; Solin O; Divgi C; Eskola O; Sorger JM; Stabin MG; Kachur A; Hahn SM; Grönroos TJ; Forsback S; Evans SM; Koch CJ; Minn H
Cancer Biother Radiopharm; 2012 Sep; 27(7):412-9. PubMed ID: 22897720
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
28. An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.
Mao X; McManaway S; Jaiswal JK; Patel PB; Wilson WR; Hicks KO; Bogle G
PLoS Comput Biol; 2018 Oct; 14(10):e1006469. PubMed ID: 30356233
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
30. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
31. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
32. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
33. Engineering
Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
[TBL] [Abstract][Full Text] [Related]
34. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Huang T; Civelek AC; Li J; Jiang H; Ng CK; Postel GC; Shen B; Li XF
J Nucl Med; 2012 Aug; 53(8):1262-8. PubMed ID: 22717978
[TBL] [Abstract][Full Text] [Related]
35. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
Salmon HW; Siemann DW
Radiother Oncol; 2004 Dec; 73(3):359-66. PubMed ID: 15588883
[TBL] [Abstract][Full Text] [Related]
36. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake.
Koch CJ; Shuman AL; Jenkins WT; Kachur AV; Karp JS; Freifelder R; Dolbier WR; Evans SM
Int J Radiat Biol; 2009 Dec; 85(12):1137-47. PubMed ID: 19995239
[TBL] [Abstract][Full Text] [Related]
37. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
38. The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study.
Zhang G; Li J; Wang X; Ma Y; Yin X; Wang F; Zheng H; Duan X; Postel GC; Li XF
J Nucl Med; 2015 Apr; 56(4):607-12. PubMed ID: 25722447
[TBL] [Abstract][Full Text] [Related]
39. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
Woods ML; Koch CJ; Lord EM
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]